Catalent (NYSE:CTLT) Upgraded by StockNews.com to “Hold” Rating

StockNews.com upgraded shares of Catalent (NYSE:CTLT) from a sell rating to a hold rating in a report published on Monday morning.

Several other equities research analysts also recently issued reports on CTLT. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. William Blair restated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Eight investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $63.40.

Catalent Stock Performance

Shares of CTLT opened at $61.45 on Monday. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The firm has a 50-day moving average of $59.93 and a 200-day moving average of $58.55. The company has a market cap of $11.15 billion, a PE ratio of -27.19, a price-to-earnings-growth ratio of 2.43 and a beta of 1.16. Catalent has a one year low of $36.74 and a one year high of $61.50.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.10) EPS. As a group, equities analysts forecast that Catalent will post 0.84 earnings per share for the current year.

Insider Activity at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,114 shares of company stock worth $305,931. Corporate insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC boosted its position in Catalent by 129.2% in the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after buying an additional 2,299,784 shares in the last quarter. Bank of Montreal Can grew its stake in shares of Catalent by 181.5% in the third quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock worth $109,388,000 after purchasing an additional 1,169,044 shares during the last quarter. National Bank of Canada FI grew its position in shares of Catalent by 300.0% in the 3rd quarter. National Bank of Canada FI now owns 1,460,813 shares of the company’s stock valued at $88,481,000 after buying an additional 1,095,578 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its position in Catalent by 166.5% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company’s stock valued at $83,733,000 after purchasing an additional 863,624 shares during the period. Finally, ING Groep NV increased its position in shares of Catalent by 162.5% during the third quarter. ING Groep NV now owns 1,130,504 shares of the company’s stock worth $68,475,000 after buying an additional 699,851 shares during the period.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.